The board of directors of Karo Pharma Aktiebolag (publ) (the "Company" or "Karo") has resolved to initiate a process to have the Company's shares listed on Nasdaq First North Growth Market and delisted from Nasdaq Stockholm (the "First North Listing"). The First North Listing is expected to be completed during the first half of 2022, in connection with the rights issue intended to repay the bridge loan facility provided to finance the acquisition of
Karo is on a journey to build a pan-European consumer healthcare company. The ongoing administration, governance and reporting requirements would be simplified (including semi-annual financial reporting), with a consequential reduction in the costs and use of managerial resources associated with having the Company's shares listed on Nasdaq Stockholm. Furthermore, the liquidity in the Company's share has been low since the completion of the tender offer from its largest shareholder,
The board of directors therefore believes that Nasdaq First North Growth Market, with its more suitable regulatory environment and lower cost of complying with continuing obligations, is a more appropriate listing venue for the Company given its strategy and shareholder base.
Further information on the First North Listing is expected to be provided no later than in connection with a potential resolution by the board of directors of the Company to submit a formal application to have its shares delisted from Nasdaq Stockholm, during the first half of 2022.
For further information, please contact:
The information was submitted for publication by the contact persons set out above, at
About
https://news.cision.com/karo-pharma/r/karo-pharma-intends-to-change-listing-venue-to-nasdaq-first-north-growth-market-during-the-first-hal,c3472360
https://mb.cision.com/Main/72/3472360/1509921.pdf
(c) 2021 Cision. All rights reserved., source